COVID-19 update: FDA continues user-fee related reviews

FDA

16 April 2020 - The U.S. FDA's User Fee programs help us fulfil our mission to protect public health while also helping to accelerate innovation in industry and bring new treatment options to the American public. 

Throughout this public health emergency, we’ve continued to execute our review activities while responding to the public health needs of the current COVID-19 pandemic.

We continue to perform our user fee review activities and our application review teams across the agency remain focused on their work as we do everything possible to maintain continuity of operations in a very dynamic situation. Part of these actions include looking at ways to use technology and established agreements with our foreign counterparts to minimise impact to applications under review.

With many staff working on COVID-19 activities, it is possible that we will not be able to sustain our current level of performance indefinitely.

Read FDA Statement

Michael Wonder

Posted by:

Michael Wonder